Iloprost: 5 agencies, 2004–2021
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
HAS (France) has been harder on iloprost than on its own caseload: it refused 2 of 5 decisive submissions here (40%), against a base rate of 11% across everything it has assessed.
The file has been open for more than a decade: 17.6 years separate the first record, 7 Apr 2004 at HAS (France), from the most recent, 25 Nov 2021 at CIPM (Spain).
TLV (Sweden) changed its position: recommended on 10 Nov 2004, restricted by 13 May 2011.
No assessment is on file from PBAC (Australia), SMC (Scotland) and G-BA (Germany), each among the eight highest-volume agencies here.
Nothing has been added since 2021; on this evidence the file is dormant.
HAS (France) was first to assess iloprost, on 7 Apr 2004; CIPM (Spain) did not open a file until 25 Nov 2021 — an unusually long tail of 17.6 years between the earliest and latest system to look at it.
The record arrives in waves: 3 separate years each carry two or more decisions, spread across 6 years in total.
2 of the 5 agencies here assessed iloprost more than once, HAS (France) most often at 5 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 5 of the 18 agencies here have assessed iloprost.
The full ledger for iloprost reads 6 recommended, 2 not recommended and 2 restricted.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| CIPM (Spain) | 25 Nov 2021 | Indicación terapéutica autorizada: Tratamiento de pacientes adultos con hipertensión pulmonar primaria, clase funcional … | financed by the SNS, on appeal · art. 92 a, c | source |
| HAS (France) | 8 Jan 2020 | Listing (Transparency Committee) | SMR insufficient · ASMR V | source |
| TLV (Sweden) | 13 May 2011 | Ny ampullstorlek av Ventavis ingår i högkostnadsskyddet med begränsning | restricted subsidy | source |
| PHARMAC (New Zealand) | 7 Nov 2007 | Pulmonary Arterial Hypertension (PAH) | PTAC advice: High · decision reached | source |
| AWMSG (Wales) | 13 Mar 2007 | Treatment of patients with primary pulmonary hypertension, classified as New York Heart Association functional class III… | recommended with restrictions (full) | source |
5 further decisions for iloprost, across 2 agencies, are not shown here. They link to 3 further source documents.
Related molecules
- rivaroxaban — same ATC class B01A — Antithrombotics
- apixaban — same ATC class B01A — Antithrombotics
- enoxaparin — same ATC class B01A — Antithrombotics
- dabigatran — same ATC class B01A — Antithrombotics
- fondaparinux — same ATC class B01A — Antithrombotics
- ticagrelor — same ATC class B01A — Antithrombotics
Coverage: 10 decisions for iloprost from 5 agencies, 2004 to 2021. Data to 7 Sep 2026. ATC class B01A — Antithrombotics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.